NASDAQ:ICLR

ICON Public Stock Forecast, Price & News

$214.46
-0.36 (-0.17 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$213.75
$216.70
50-Day Range
$194.07
$232.20
52-Week Range
$157.05
$234.22
Volume527,815 shs
Average Volume563,218 shs
Market Capitalization$11.50 billion
P/E Ratio33.83
Dividend YieldN/A
Beta0.85
30 days | 90 days | 365 days | Advanced Chart
Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.


ICON Public logo

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

261st out of 2,100 stocks

Commercial Physical Research Industry

5th out of 37 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ICON Public (NASDAQ:ICLR) Frequently Asked Questions

Is ICON Public a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICON Public stock.
View analyst ratings for ICON Public
or view top-rated stocks.

What stocks does MarketBeat like better than ICON Public?

Wall Street analysts have given ICON Public a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ICON Public wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ICON Public's next earnings date?

ICON Public is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for ICON Public
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) issued its quarterly earnings data on Tuesday, April, 27th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.97 by $0.09. The medical research company had revenue of $858.20 million for the quarter, compared to analysts' expectations of $780.49 million. ICON Public had a trailing twelve-month return on equity of 20.70% and a net margin of 11.49%.
View ICON Public's earnings history
.

How has ICON Public's stock price been impacted by Coronavirus?

ICON Public's stock was trading at $152.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ICLR shares have increased by 40.6% and is now trading at $214.46.
View which stocks have been most impacted by COVID-19
.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided earnings per share guidance of 8.400-8.800 for the period, compared to the Thomson Reuters consensus estimate of $8.310. The company issued revenue guidance of $3.40 billion-$3.50 billion, compared to the consensus revenue estimate of $3.24 billion.

What price target have analysts set for ICLR?

10 analysts have issued 12 month target prices for ICON Public's shares. Their forecasts range from $200.00 to $280.00. On average, they anticipate ICON Public's share price to reach $236.00 in the next year. This suggests a possible upside of 10.0% from the stock's current price.
View analysts' price targets for ICON Public
or view top-rated stocks among Wall Street analysts.

Who are ICON Public's key executives?

ICON Public's management team includes the following people:
  • Dr. Steven A. Cutler, CEO & Director (Age 61, Pay $2.21M)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 42, Pay $914k) (LinkedIn Profile)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas N. O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 46) (LinkedIn Profile)
  • Mr. Simon Holmes, Exec. VP of Investor Relations & Corp. Devel. (Age 54) (LinkedIn Profile)
  • Ms. Niamh Murphy, Director of Corp. Communications (LinkedIn Profile)
  • David Green, VP of Marketing
  • Mr. Joe Cronin, Chief HR Officer (LinkedIn Profile)
  • Ms. Dana Lynn Poff, Exec. VP of Program Management (LinkedIn Profile)

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public CEO Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among ICON Public's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ICON Public's key competitors?

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), The Walt Disney (DIS), The Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a number of retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.22%), Todd Asset Management LLC (0.19%), Globeflex Capital L P (0.12%), Natixis Advisors L.P. (0.11%), Captrust Financial Advisors (0.05%) and Handelsbanken Fonder AB (0.04%).

Which major investors are selling ICON Public stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Todd Asset Management LLC, Captrust Financial Advisors, Chartwell Investment Partners LLC, Natixis Advisors L.P., Globeflex Capital L P, We Are One Seven LLC, and Fieldpoint Private Securities LLC.

Which major investors are buying ICON Public stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, FDx Advisors Inc., Tributary Capital Management LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Handelsbanken Fonder AB, KB Financial Partners LLC, Fayez Sarofim & Co, and Cullen Frost Bankers Inc..

How do I buy shares of ICON Public?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $214.46.

How much money does ICON Public make?

ICON Public has a market capitalization of $11.50 billion and generates $2.80 billion in revenue each year. The medical research company earns $332.33 million in net income (profit) each year or $6.53 on an earnings per share basis.

How many employees does ICON Public have?

ICON Public employs 15,730 workers across the globe.

Does ICON Public have any subsidiaries?

The following companies are subsidiares of ICON Public: Addplan Inc., Beacon Bioscience Inc., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, Molecular MD Corp., Oxford Outcomes Ltd, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., and VSK (Kenilworth) Limited.

When was ICON Public founded?

ICON Public was founded in 1990.

What is ICON Public's official website?

The official website for ICON Public is www.iconplc.com.

Where are ICON Public's headquarters?

ICON Public is headquartered at SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000.

How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at (531) 291-2000.


This page was last updated on 6/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.